Virax Biolabs Group Ltd Financials
Virax Biolabs Group Ltd (VRAX) reported $12K in revenue for fiscal year 2026, up 96.2% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 6 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
The business is financed by recurring external capital while its operating cost base remains many times larger than reported revenue.
In FY2026, the net loss narrowed17.1% from the prior year, but operating cash outflow increased1.3% . That divergence means the accounting improvement did not produce better cash conversion, the central economic constraint visible in the filings.
Reported sales were only
The balance sheet provides short-term liquidity: cash was
Financial Health Signals
Virax Biolabs Group Ltd does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.
Virax Biolabs Group Ltd passes 6 of 8 computable financial strength tests (1 of the nine could not be computed from available data). 2 of 4 profitability signals pass, all 3 leverage/liquidity signals pass, both operating efficiency signals pass.
Virax Biolabs Group Ltd reported a net loss of $5.0M while operations used $4.6M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Key Financial Metrics
Earnings & Revenue
Virax Biolabs Group Ltd generated $12K in revenue in fiscal year 2026. This represents an increase of 96.2% from the prior year.
Virax Biolabs Group Ltd reported -$5.0M in net income in fiscal year 2026. This represents an increase of 17.1% from the prior year.
Not reported for fiscal year 2026.
Not reported for fiscal year 2026.
Cash & Balance Sheet
Virax Biolabs Group Ltd recorded an outflow of $4.9M in free cash flow in fiscal year 2026, representing a cash shortfall after capex. This represents an increase of 5.6% from the prior year.
Virax Biolabs Group Ltd held $4.2M in cash against $305K in long-term debt as of fiscal year 2026.
Not reported for fiscal year 2026.
Margins & Returns
Virax Biolabs Group Ltd's ROE was -68.6% in fiscal year 2026, measuring profit generated per dollar of shareholder equity. This is up 42.5 percentage points from the prior year.
Not reported for fiscal year 2026.
Not reported for fiscal year 2026.
Not shown for fiscal year 2026: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Capital Allocation
Virax Biolabs Group Ltd invested $256K in capex in fiscal year 2026, funding long-term assets and infrastructure. This represents a decrease of 57.6% from the prior year.
Not reported for fiscal year 2026.
Not reported for fiscal year 2026.
VRAX Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | FY26 | FY25 | FY24 | FY23 | FY22 | FY21 |
|---|---|---|---|---|---|---|
| Revenue | $12K+96.2% | $6K-96.0% | $156K+1727.1% | $9K | $0-100.0% | $124K |
| Interest Expense | $46K0.0% | $46K+73.1% | $26K | N/A | N/A | N/A |
| Income Tax | -$900K-558.7% | -$137K | N/A | N/A | N/A | N/A |
| Net Income | -$5.0M+17.1% | -$6.1M+10.0% | -$6.7M-23.5% | -$5.5M | N/A | N/A |
Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit, R&D Expenses, SG&A Expenses, Operating Income, EPS (Diluted).
VRAX Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | FY26 | FY25 | FY24 | FY23 | FY22 | FY21 |
|---|---|---|---|---|---|---|
| Total Assets | $8.3M+29.5% | $6.4M+17.2% | $5.5M-44.1% | $9.8M+20046.2% | $49K+22.9% | $40K |
| Current Assets | $6.8M+39.5% | $4.9M+11.7% | $4.4M-54.5% | $9.6M+19679.9% | $49K+22.9% | $40K |
| Cash & Equivalents | $4.2M0.0% | $4.2M+17.8% | $3.6M-61.6% | $9.4M+42888.3% | $22K+23.5% | $18K |
| Inventory | $95K0.0% | $95K+56.8% | $60K | $0-100.0% | $21K-0.6% | $21K |
| Goodwill | N/A | N/A | N/A | $178K | N/A | N/A |
| Total Liabilities | $990K+2.6% | $965K+179.5% | $345K-62.0% | $908K-27.1% | $1.2M+42.9% | $871K |
| Current Liabilities | $685K+1.8% | $673K+298.7% | $169K-81.4% | $908K-27.1% | $1.2M+42.9% | $871K |
| Long-Term Debt | $305K+4.5% | $292K+65.3% | $176K | N/A | N/A | N/A |
| Total Equity | $7.3M+34.3% | $5.5M+6.3% | $5.1M-42.3% | $8.9M+844.0% | -$1.2M-43.9% | -$832K |
| Retained Earnings | -$29.6M-20.4% | -$24.6M-32.7% | -$18.5M-57.1% | -$11.8M-86.1% | -$6.3M-36.9% | -$4.6M |
Not reported in any period shown, so not listed: Accounts Receivable.
VRAX Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | FY26 | FY25 | FY24 | FY23 | FY22 | FY21 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -$4.6M-1.3% | -$4.6M+26.9% | -$6.2M-49.5% | -$4.2M | N/A | -$590K |
| Capital Expenditures | $256K-57.6% | $604K-36.6% | $952K | N/A | N/A | N/A |
| Free Cash Flow | -$4.9M+5.6% | -$5.2M+28.2% | -$7.2M | N/A | N/A | N/A |
| Investing Cash Flow | -$256K+57.6% | -$604K+48.1% | -$1.2M-552.7% | -$178K | N/A | N/A |
| Financing Cash Flow | $7.1M+22.1% | $5.8M+252.3% | $1.6M-88.0% | $13.7M | N/A | $585K |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
VRAX Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples.
| Metric | FY26 | FY25 | FY24 | FY23 | FY22 | FY21 |
|---|---|---|---|---|---|---|
| Net Margin | -40507.0% | -95833.7% | -4308.4% | -63751.5% | N/A | N/A |
| Return on Equity | -68.6%+42.5pp | -111.1%+20.1pp | -131.1%-69.8pp | -61.3% | N/A | N/A |
| Return on Assets | -60.5%+33.9pp | -94.4%+28.5pp | -122.9%-67.3pp | -55.6% | N/A | N/A |
| Current Ratio | 9.97+2.7x | 7.27-18.7x | 25.94+15.3x | 10.61+10.6x | 0.040.0x | 0.05 |
| Debt-to-Equity | 0.040.0x | 0.050.0x | 0.03-0.1x | 0.10 | N/A | N/A |
| FCF Margin | -39263.7% | -81621.6% | -4602.7% | N/A | N/A | N/A |
Not reported in any period shown, so not listed: Gross Margin, Operating Margin.
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Net Margin, FCF Margin.
Similar Companies
Where Virax Biolabs Group Ltd Ranks
Frequently Asked Questions
What is Virax Biolabs Group Ltd's annual revenue?
Virax Biolabs Group Ltd (VRAX) reported $12K in total revenue for fiscal year 2026. This represents a 96.2% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Virax Biolabs Group Ltd's revenue growing?
Virax Biolabs Group Ltd (VRAX) revenue grew by 96.2% year-over-year, from $6K to $12K in fiscal year 2026.
Is Virax Biolabs Group Ltd profitable?
No, Virax Biolabs Group Ltd (VRAX) reported a net income of -$5.0M in fiscal year 2026.
How much debt does Virax Biolabs Group Ltd have?
As of fiscal year 2026, Virax Biolabs Group Ltd (VRAX) had $4.2M in cash and equivalents against $305K in long-term debt.
What is Virax Biolabs Group Ltd's return on equity (ROE)?
Virax Biolabs Group Ltd (VRAX) has a return on equity of -68.6% for fiscal year 2026, measuring how efficiently the company generates profit from shareholder equity.
What is Virax Biolabs Group Ltd's free cash flow?
Virax Biolabs Group Ltd (VRAX) recorded an outflow of $4.9M in free cash flow during fiscal year 2026. This represents a 5.6% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Virax Biolabs Group Ltd's operating cash flow?
Virax Biolabs Group Ltd (VRAX) recorded an outflow of $4.6M in operating cash flow during fiscal year 2026, representing cash used by core business activities.
What are Virax Biolabs Group Ltd's total assets?
Virax Biolabs Group Ltd (VRAX) had $8.3M in total assets as of fiscal year 2026, including both current and long-term assets.
What are Virax Biolabs Group Ltd's capital expenditures?
Virax Biolabs Group Ltd (VRAX) invested $256K in capital expenditures during fiscal year 2026, funding long-term assets and infrastructure.
What is Virax Biolabs Group Ltd's current ratio?
Virax Biolabs Group Ltd (VRAX) had a current ratio of 9.97 as of fiscal year 2026, which is generally considered healthy.
What is Virax Biolabs Group Ltd's debt-to-equity ratio?
Virax Biolabs Group Ltd (VRAX) had a debt-to-equity ratio of 0.04 as of fiscal year 2026, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Virax Biolabs Group Ltd's return on assets (ROA)?
Virax Biolabs Group Ltd (VRAX) had a return on assets of -60.5% for fiscal year 2026, measuring how efficiently the company uses its assets to generate profit.
How does Virax Biolabs Group Ltd's liquidity compare with its operating cash outflow?
At the end of fiscal year 2026, Virax Biolabs Group Ltd (VRAX) held $4.2M in cash, cash equivalents and investments, and reported an operating cash outflow of $4.6M over that year. Dividing the one by the other, the reported balance equals about 11 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
What is Virax Biolabs Group Ltd's Piotroski F-Score?
Virax Biolabs Group Ltd (VRAX) has a Piotroski F-Score of 6 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Virax Biolabs Group Ltd's earnings high quality?
Virax Biolabs Group Ltd (VRAX) reported a net loss of $5.0M while operations used $4.6M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.